The long-term clinical results of a platelet glycoprotein IIb/IIIa receptor blocker (abciximab: ReoPro®) coated stent in patients with coronary artery disease

Korean Journal of Internal Medicine

Volumn 19, Issue 4, 2004, Pages 220-229

  Kim, Weon ^a   Jeong, Myung Ho ^a   Hong, Young Joon ^a   Lee, Seng Hyun ^a   Park, Woo Seok ^a   Kim, Ku Han ^a   Kim, In Soo ^a   Choi, Myung Ja ^a   Ahn, Young Keun ^a   Cho, Jeong Gwan ^a   Park, Jong Chun ^a   Cho, Dong Lyun ^b   Kim, Hoon ^b   Kang, Jung Chaee ^a  

^a Chonnam National University Medical School   (South Korea)

^b Chonnam National University   (South Korea)

Author keywords

Coronary Artery Diseases; Platelets; Restenosis; Stents

Indexed keywords

ABCIXIMAB; FIBRINOGEN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BIOMATERIAL; FIBRINOGEN RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD VESSEL DIAMETER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; TREATMENT OUTCOME; CORONARY ARTERY ATHEROSCLEROSIS; DRUG ANTAGONISM; FEMALE; KOREA; MALE; MIDDLE AGED; PROSPECTIVE STUDY; STENT;

ANTIBODIES, MONOCLONAL; COATED MATERIALS, BIOCOMPATIBLE; CORONARY ARTERIOSCLEROSIS; CORONARY RESTENOSIS; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; KOREA; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROSPECTIVE STUDIES; STENTS;

EID: 14844288946     PISSN: 12263303     EISSN: None     Source Type: Journal    
DOI: 10.3904/kjim.2004.19.4.220     Document Type: Article

References (30)

1. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P. A comparison of balloon-expandable stent implantation with balloon angioplasty in patients with coronary artery disease. N Eng J Med 331-489-495, 1994
2. Fischman DL, Leon MB, Bairn DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M. A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 331:496-501, 1994
3. Herdeg C, Oberhoff M, Baumbach A, Blattner A, Axel DI, Schroder S, Heinle H, Karsch KR. Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo. J Am Coll Cardiol 35:1969-1976, 2000
4. Leon MB, Teirstein PS, Moses JW, Tripuraneni P, Lansky AJ, Jani S, Wong SC, Fish D, Ellis S, Holmes DR, Kerieakes D, Kuntz RE. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med 344:250-256, 2001
5. Waksman R, Bhargava B, White L, Chan RC, Mehran R, Lansky AJ, Mintz GS, Satler LF, Pichard AD, Leon MB, Kent KK. Intracoronary beta-radiation therapy inhibits recurrence of in-stent restenosis. Circulation 101:1895-1898, 2000
6. Morice MC, Serruy PW, Sousa JE, Fajadet J, Ban Hayashi E, Perm M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R. A randomized comparison of a sirolimus-eluting stent with standard stent for coronary revascularization. N Engl J Med 346:1773-1780, 2002
7. EPIC (Evaluation of 7E3 in Preventing Ischemic Complications) Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 330:956-961, 1994
8. EPILOG (Evaluation in PTCA to improve Long-Term outcome GP IIb/IIIa Blockade Study Group) Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 336:1689-1696, 1997
9. CAPTURE (C7E3 Fab AntiPlatelet Therapy in Unstable Refractory angina) Investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina. Lancet 349:1429-1435, 1997
10. Platelet Receptor Inhibition in ischemic Syndrome Management in Patients Limited by Unstable Sings and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 338:1488-1497, 1998
11. Nakada MT, Jordan RE, Knight DM. Abciximab (ReoPro, chimeric 7E3 Fab) cross-specificity with [alpha]V [beta]3 integrin receptors: a potential mechanism for the prevention of restenosis. J Am Coll Cardiol 29:A243, 1997
12. Reverter JC, Beguin S, Kessels H, Kuman R, Hemker HC, Coller BS. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody potential implications for the effect of c7E3 Fab treatment of an acute thrombosis and "clinical restenosis." J Clin Invest 98:863-874, 1996
13. Shappel SB, Toman C, Anderson DC, Taylor AA, Entman ML, Smith CW. Mac-1 (CD11b/CD8) mediates adherence-dependent hydrogen peroxide production by human and canine neutrophils. J Immunol 144:2702-2711, 1990
14. Simon DI, Xu H, Ortelpp S, Rogers C, Rao NK. 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler Thromb Vasc Biol 17:528-535, 1997
15. Mickelson JK, Ali MN, Kleiman NS, Lakkis NM, Chow TW, Hughes BJ, Smith CW. Chimeric 7E3 Fab (ReoPro) decreases detectable CD IIb on neutrophils from patients undergoing coronary angioplasty. J Am Coll Cardiol 3397-106, 1999
16. Lefkovits J, Topol EJ. Platelet glycoprotein IIb/IIIa receptor antagonists in coronary artery disease. Eur Heart J 17:9-18, 1996
17. Kang KT, Jeong MH, Kim NH, Lee SH, Rhew JY, Park JC, Lee SU, Kim KH, Ahn YK, Cho JG, Park JC, Cho DL, Kang JC. The inhibitory effect of platelet glycoprotein IIb/IIIa receptor blocker-coated stent on porcine coronary stent restenosis. Korean Med J 60:314-323, 2001
18. Ryan TJ, Faxon DP, Gunnar RM, Kennedy JW, King SB 3rd, Loop FD, Peterson KL, Reeves TJ, Williams DO, Winters WL Jr. Guidelines for percutaneous transluminal coronary angioplasty: a report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). Circulation 78:486-502, 1988
19. Weitz JI, Bates SM. Beyond heparin and aspirin: new treatments for unstable angina and non-Q wave myocardial infarction. Arch Intern Med 160:749-758, 2000
20. Welt FG, Rogers C. Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol 22:1769-1776, 2002
21. Virmani R, Farb A. Pathology of in-stent restenosis. Curr Opin Lipidol 10:499-506, 1999
22. Lincoff AM, Kereiakes DJ, Mascelli MA, Deckelbaum LI, Barnathan ES, Patel KK, Frederick B, Nakada MT, Topol EJ. Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation 104:163-167, 2001
23. Schwarz M, Nordt T, Bode C, Peter K. The GP IIb/IIIa inhibitor abciximab (c7E3) inhibits the binding of various ligands to the leukocyte integrin Mac-1 (CD11b/CD18, alpha(M)beta(2)). Thromb Res 107:121-128, 2002
24. Park OY, Jeong MH, Kim JH, Kim W, Lim SY, Sim DS, Yang BR, Lee SH, Lee SH, Hong YJ, Kim JH, Park WS, Ahn YG, Park JT, Cho JG, Cho DR, Park JC, Kang JC. The inhibitory effect of platelet glycoprotein IIb/IIIa receptor blocker-coated stent on porcine coronary stent restenosis. Korean Circ J 33:439-445, 2003
25. Willerson JT, Golino P, Eidt J, Campbell WB, Buja LM. Specific platelet mediators and unstable coronary artery lesions. Circulation 80:198-205, 1989
26. Blindt R, Bosserhoff AK, Zeiffer U, Krott N, Hanrath P, vom Dahl J. Abciximab inhibits the migration and invasion potential of human coronary artery smooth muscle cells. J Mol Cell Cardiol 32:2195-2206, 2000
27. EPISTENT Investigators. Randomized placebo-controlled and balloon angioplasty -controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 352:87-92, 1998
28. ERASER (Evaluation of Reo-Pro And Stenting to Eliminate Restenosis) Investigators. Acute platelet inhibition with abciximab does not reduce in-stent restenosis. Circulation 100:799-806, 1999
29. Aggarwal RK, Ireland DC, Azrin MA, Ezekowitz MD, de Bono DP, Gershlick AH. Antithrombolic potential of polymer-coated stents eluting platelet glycoprolein IIb/IIIa receptor antibody. Circulation 94:3311-3317, 1996
30. Baron JH, Gershlick AH, Hogrefe K, Armstrong J, Holt CM, Aggarwal RK, Azrin M, Ezekowitz M, de Bono DP. In vitro evaluation of c7E3-Fab (ReoPro) eluting polymer-coated coronary stents. Cardiovasc Res 46:585-594, 2000